One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

This trial is testing JCXH-213 — a new CAR-T cell therapy that targets the CD19 protein on cancer cells — in people with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). This includes several types of B-cell lymphoma that have come back or stopped responding after prior treatments. **You may be eligible if...** - You have been confirmed to have CD19-positive B-cell non-Hodgkin lymphoma (including DLBCL, follicular lymphoma, PMBCL, HGBCL, or transformed B-cell lymphoma) - Your cancer has relapsed or did not respond to prior treatment - You are in reasonably good health (ECOG score 0–1) - You have measurable lymphoma on scans - Your organ function meets the required levels **You may NOT be eligible if...** - You have active brain involvement from the lymphoma - You have had certain prior CAR-T or gene therapies - You have serious infections, autoimmune conditions, or organ failure Talk to your doctor to see if this trial is right for you.